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The emergence of multidrug-resistant strains of Mycobacterium tuberculosis (MTB), the bacte-
rium responsible for tuberculosis (TB), has rekindled the interest in the role of nutritional
supplementation of micronutrients, such as vitamin D, as adjuvant treatment. Here, the
growth of virulent MTB in macrophages obtained from the peripheral blood of patients with
and without TB was studied. The H37Rv strain genetically modified to express Vibrio harveyi
luciferase was used to determine the growth of MTB by luminometry in the human mono-
cyte-derived macrophages (hMDMs) from study subjects. Determination of cytokine levels
in culture supernatants was performed using a flow cytometry-based bead array technique.
No differences in intracellular growth of MTB were observed between the different study
groups. However, stimulation with 100 nM 1,25-dihydroxyvitamin D significantly enhanced
the capacity of hMDMs isolated from TB patients to control the infection. This effect was
not observed in hMDMs from the other groups. The interleukin (IL)-1b and IL-10 release by
hMDMswas clearly increased upon stimulation with 1,25-dihydroxyvitamin D. Furthermore,
the 1,25-dihydroxyvitamin D stimulation also led to elevated levels of TNF-a (tumor necrosis
factor-alpha) and IL-12p40. It was concluded that vitamin D triggers an inflammatory
response in human macrophages with enhanced secretion of cytokines, as well as enhanc-
ing the capacity of hMDMs from patients with active TB to restrict mycobacterial growth.
 2013 Asian-African Society for Mycobacteriology. All rights reserved.-African Society for Mycobacteriology. All rights reserved.
el 12, Faculty of Health Sciences, 58185 Linko¨ping, Sweden. Tel.: +46 10 1034779.
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Introduction
Tuberculosis (TB), once considered a disease of the past, ow-
ing to the discovery of effective antibiotics, is today the num-
ber one cause of death from bacterial infections worldwide. In
the pre-antibiotic era, the infection was primarily treated in
sanatoria, where a nutritious diet and outdoor rest were
important components of the therapy. The emergence of mul-
tidrug-resistant strains of Mycobacterium tuberculosis (MTB),
the bacterium responsible for the disease, has rekindled the
interest in nutritional aspects of TB treatment in recent years.
Several groups, including this one, have performed studies to
investigate the role of vitamins (vitamin A and D), minerals
(zinc) and amino acids like L-arginine as adjuvants to the
standard chemotherapy of TB [1–4]. In 2006, Liu et al. showed
that vitamin D enhances the ability of human monocytes to
control intracellular growth of MTB [5], and that it was a pro-
cess depending on an increased expression of the vitamin D
receptor (VDR) and enhanced production of the anti-microbial
peptide cathelicidin, upon engagement of Toll-like receptors
(TLRs) 2 and 1. Cathelicidin was later shown to be crucial
for the control of mycobacterial growth in THP-1 cells [6].
These mechanistic studies on the relationship between vita-
min D and the ability of immune cells to control MTB encour-
aged further clinical and experimental studies on the role of
vitamin D-deficiency as a risk factor for TB. Clinical studies
have so far been inconclusive and have shown both an effect
of vitamin D in subgroup analysis of patients with specific
VDR polymorphisms [1], and a lack of any clinical improve-
ment or effects on mortality from vitamin D supplementation
[4]. Most experimental studies have been performed with
monocytes or macrophage-like cell lines, and so far none
has studied the ability of vitamin D to enhance the anti-
mycobacterial capacity of monocyte-derived macrophages
isolated from patients with active TB. Here, the growth of vir-
ulent MTB was studied in hMDMs from patients carefully cat-
egorized with having active, previous or latent TB and how
this was affected by stimulation with 1,25-dihydroxyvitamin
D3 (the active form of vitamin D, hereafter referred to as
1,25D3).Study population and methods
Study population
Patients who were investigated because of persistent cough
and/or exposure to TB were included in the study after in-
formed and written consent. The study protocol was ap-
proved by the Ethical Committee of Linko¨ping University,
Sweden. Patients were classified by a senior pulmonary phy-
sician and a senior thoracic radiologist as non-TB, previous
TB, current TB or latent TB (LTB) according to published guide-
lines [7]. The classification was performedwithout knowledge
of the experimental results. Non-TB were patients with nega-
tive PPD/IGRA-test, normal chest X-ray and/or high resolution
computer tomography (HRCT), and bronchoscopy (performed
because of persistent cough) with negative mycobacterial cul-
tures (C1–C3, C5–C9, C12–C14; n = 11). Previous TB were pa-
tients with a medical history of previous TB and/orradiological findings on chest X-ray and/or HRCT consistent
and/or IGRA-test, but negative cytology and negative myco-
bacterial cultures/PCR by bronchoscopy (PTB1–PTB7; n = 7).
Current TB were patients treated for TB because of a positive
mycobacterial culture and/or clinical and radiological symp-
toms suggestive of active TB (TB1–TB8, TB10–12, n = 11). TB-
exposed subjects exhibiting positive TST and/or positive
IGRA, but no clinical and radiological signs of TB were catego-
rized as latent TB (LTB1–LTB4, LTB6–LTB7 n = 6). At least two of
three criteria were required for a LTB diagnosis. A positive TST
was defined as P10 mm, since most of the subjects included
displayed a scar after previous vaccination. None of the pa-
tients investigated was treated with TB drugs when blood
samples were collected. All patients were HIV-negative. The
patient characteristics are presented in Table 1.
Preparation of macrophages
Human monocyte-derived macrophages (hMDMs) were pre-
pared from monocytes isolated from heparinized blood as
previously described [8] using routine methods, with the
modification that differentiation was performed during 5–
7 days in DMEM with 10% human serum (pooled from five
healthy donors); hMDM were seeded in 96-well plates (Sar-
stedt) one day prior to infection in DMEM free of antibiotics
(100,000 cells/well).
Bacteria
The virulent MTB strain H37Rv (American Type Culture Col-
lection) harboring a pSMT1-plasmid encoding Vibrio harveyi
luciferase [9,10] were grown in Middlebrook 7H9 broth supple-
mented with TWEEN 80 and oleic acid-albumin-dextrose-cat-
alase (OADC) (BD) for 2 to 3 weeks at 37 C with 100 lg/ml
hygromycin for selection before being re-inoculated in fresh
broth and incubated for 7 days to reach early log phase. Prior
to infection, bacteria were prepared as previously described
[11]. Briefly, bacterial suspensionwaswashed and re-suspended
in DMEM and a single-bacillus suspension was obtained via a
sterile syringe equippedwith a 27-gauge needle. The concentra-
tion was determined by using optical density at 600 nm (OD600)
as a function of colony-forming units (CFU)/ml.
Infection procedure
A pulse-chase approach was used to infect hMDMs, where
bacteria were added to the hMDMs in a serum-free medium
at a multiplicity of infection (MOI) of 10 and incubated at
37 C for 1 h. The infection was followed by a change of med-
ium to serum-containing antibiotic-free DMEM with 100 nM
1,25D3 (Sigma–Aldrich). Control wells were given medium
without added 1,25D3.
Quantiferon assay
In the QuantiFERON-TB Gold in-Tube assay (Cellestis, Aus-
tralia), blood samples were collected in tubes provided by
the manufacturer. Samples were shaken and incubated at
Table 1 – Characteristics of the population studied. Data are presented as means ± SD. Significant difference from ‘‘non-TB’’
subjects is indicated.
Non-TB
subjects
Previous TB
infection
Active TB infection Latent TB infection
Subjects 11 7 11 6
Mean age, year 51 ± 16 52 ± 13 42 ± 19 51 ± 12
Females/males 7/4 4/3 6/5 3/3
Ethnicity Caucasians 10
Asians 1
Caucasians 4
Africans 3
Caucasians 7
Africans 3
Asians 1
Caucasians 4
Africans 2
Current smokers (%) 3 (27%) 0 (0%) 4 (36%) 2 (33%)
Present BCG scar (%) 10 (91%) 4 (57%) Unknown
in two cases
4 (36%) Unknown
in two cases
4 (66%)
TB skin test, mm 3 ± 5 (n = 8) 14 ± 5** (n = 6) 18 ± 3*** (n = 8) 17 ± 6*** (n = 6)
BMI (kg/m2) 24 ± 4 (n = 11) 28 ± 3 (n = 7) 21 ± 3 (n = 11) 24 ± 5 (n = 5)
Serum-albumin (g/l) 42 ± 4 (n = 11) 40 ± 4 (n = 7) 38 ± 5 (n = 11) 41 ± 4 (n = 5)
Radiologic findings Normal 10
Smalla benign
tumor 1
Possibly inactive 6
Possibly active 1
Possibly inactive 2
Possibly active 6
Active 3
Normal 6
Serum 25-OH Vitamin D (nmol/l) 34.5 ± 25.9 27.2 ± 21.8 27.4 ± 26.9 45.8 ± 52.7
Serum quantiferon positive (%) 1 (11%)b 6 (86%) 11 (100%) 5 (83%)
Subjects w/cough 8 5 8 0
Haemoptysis 0 2 4 0
Night sweats 1 3 5 1
Heart rate > 100 0 0 2 0
Body temp > 38 C 0 0 4 0
Anemia, Hb < 120 3 0 0
** p < 0.01 (Students t-test, unpaired analysis).
*** p < 0.001 (Students t-test, unpaired analysis).
a Later diagnosed as a benign tumor.
b IGRA level in the grey zone (0.93 IU/ml), close to the cut off value for a positive test (0.35 IU/ml).
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(IU/ml) according to the instructions from the manufacturer.
Measurement of 25-hydroxyvitamin D in serum
The major circulating metabolite of vitamin D, 25-hydroxyvi-
tamin D, was measured by ELISA (Immmundiagnostik, Ger-
many) according to the manufacturer´s instructions.
Measurement of bacterial growth
The number of viable bacteria was acquired through the mea-
surement of flash-luminescence with a GloMaxMulti-Detec-
tion System (Promega) as previously described [11]. It was
previously shown that this method, based on flash-lumines-
cence emitted from the luciferase-expressing bacteria when
given the luciferase substrate n-decanal, correlates well to
CFUs and displays less variation than classic CFU assays
[11]. Measurements were performed one hour after the
pulse-chase and after two days of incubation. Results are ex-
pressed as arbitrary luminescence units (ALU) or as fold-
change of MTB growth (Day 2/Day 0).
Measurement of cytokine release
To quantify the concentrations of cytokines produced by MTB-
infected hMDMs, BDTM Cytometric Bead Array Flex Set (BD) was
used according to the manufacturer’s instructions. Briefly, cul-
ture supernatants from infected hMDMs were collected at 24 h
post-infection, aliquoted and kept at 70 C until further use.For analysis, samples were centrifuged at 10,000g for 10min
prior to dilution and mixing with cytokine-specific beads. The
supernatant-bead suspensions were incubated for 1 h at RT,
followed by 2 h of incubation in the presence of cytokine-spe-
cific PE-conjugated detection antibodies. To sterilize samples,
4% paraformaldehyde (PFA) was added for 1 h before the final
wash step. The quantification was performed by flow cytome-
try (Gallios Flow Cytometer, Beckman Coulter) where each
bead population was separated by a unique ratio of APC and
APC-Cy7, and the fluorescence intensity of PE corresponded
to the concentration of the specific cytokine, derived from a
standard curve of known cytokine concentrations.
Statistics
To evaluate the effects of 1,25D3 stimulation within each
group and comparison of the total non-stimulated with stim-
ulated samples, a paired Student’s t-test was used. The
means between different study groups were compared using
ANOVA with Bonferroni’s post hoc test. Differences between
groups are shown as *(p < 0.05) or **(p < 0.01) or ***(p < 0.001).
Results
Clinical observations of patients
Patients were classified by a senior pulmonologist into non-
TB, previous TB, current TB and latent TB, as described in Ta-
ble 1. The mean age of the patients ranged from 42 to
Fig. 1 – Phagocytosis and growth of H37Rv in hMDMs. Cells from the four studied groups of patients were infected with H37Rv
at MOI 10 as described, before luminescence was determined 1 h after pulse-chase (D0 value) as a measure of phagocytosis.
After an additional 48 h of incubation, luminescence was measured again and growth was evaluated (D2 value). (A)
Luminescence (expressed as arbitrary luminescence units, ALU) emitted from lysate- and supernatant-associated bacteria
after 1 h after pulse-chase. (B) Relative growth of H37Rv (D2/D0) in the cells of individual patients, with indicated proportions
of the relative growth in the supernatant (open bars) and lysate (black bars). (C) The mean ALU (intracellular + extracellular)
value of each of the groups 1 h after pulse-chase (phagocytosis). (D) The mean relative growth (intracellular + extracellular) at
day 2 post-infection from each group is shown. Non-TB (n = 11), previous TB (n = 7), current TB (n = 11) and latent TB (n = 6).
Bar graphs show the mean and SEM. The means were compared using ANOVA with Bonferroni’s post hoc test.
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nicity (Caucasians constituting the majority). There were no
significant differences in mean age or body mass index
(BMI) between the groups. The mean levels of serum 25-OH
vitamin D ranged from 27.4 nmol/l in the group of patients
with previous TB to 48.1 nmol/l in patients with latent TB
with no significant differences detected (Table 1).Uptake and growth of MTB
For ex vivo analysis of the capacity of the patient and control
hMDMs to control MTB, cells were infected with H37Rv. It was
previously shown that the bacterial load of hMDMs is a criti-
cal determinant of the ability of macrophages to control the
infection [12,13]. Therefore, the phagocytic capacity of the
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luciferase-expressing H37Rv in a pulse-chase approach, and
the number of cell-associated and free bacteria was deter-
mined using luminometry. As shown in Fig. 1A and C, the
phagocytic capacity of the cells (expressed as arbitrary lumi-
nescence units [ALU] at Day 0 [D0]) varied between individu-
als, but showed no significant differences between study
groups, with the non-TB and current TB group being very sim-
ilar. Next, the relative intracellular growth of MTB in hMDMs
(Fig. 1B and D) was determined after two days of infection, but
no differences could be observed between hMDMs obtained
from non-TB patients compared to cells from patients with
previous, latent or active TB.
Effect of 1,25D3 on bacterial growth
To assess the effects of 1,25D3 on the capacity of the macro-
phages to control bacterial growth, the cells were exposed
to 100 nM 1,25D3 immediately after the pulse-chase infection,
and the bacterial load was analyzed at day 2. Fig. 2 shows that
stimulation of the cells with 1,25D3 significantly reduced bac-
terial growth in hMDMs from patients with current TB
(p = 0.044), whereas there was no significant reduction in the
other groups (Fig. 2) or when cells from all groups were eval-
uated together as non-stimulated or 1,25D3-stimulated (not
shown). Initial experiments included stimulation of hMDMs
with 100 nM of the inactive metabolite 25-hydroxyvitamin
D, but this did not result in any significant effect on bacterial
growth in cells obtained from patients with current TB
(p = 0.36, data not shown), and was therefore excluded for fur-
ther experiments.Fig. 2 – Effects of 1,25D3 on bacterial growth. hMDMs were
infected with H37Rv for two days at MOI 10. Measurements
were performed at 1 h after pulse-chase (D0 value) and at
day 2 post-infection (D2 value). The figure shows the relative
growth (intracellular + extracellular) of H37Rv (D2/D0) in the
absence or presence of 100 nM 1,25D3 in the four study
groups. All patients where stimulation experiments were
performed are shown. Non-TB (n = 10), previous TB (n = 6),
current TB (n = 6) and latent TB (n = 5). Bar graphs show the
mean and SEM. Differences in growth with or without
1,25D3 stimulation within each group was tested by a
paired Student’s t-test.Cytokine analysis
To evaluate how macrophages from patients with and with-
out TB responded to MTB in the presence or absence of
1,25D3, both pro-inflammatory (interleukin [IL]-1b, tumor
necrosis factor-a [TNF-a] and IL-12p40) and anti-inflamma-
tory cytokines (IL-10) in cell supernatants one day after infec-
tion were analyzed. Stimulation with 1,25D3 significantly
increased the levels of IL-1b in hMDMs from non-TB subjects
(Fig. 3A, p = 0.039) and of IL-10 in subjects with current TB
(Fig. 3C, p = 0.028). TNF-a and IL-12p40 were not significantly
altered in the different study groups. There was a tendency
towards an increase in IL-1b-production upon 1,25D3 stimula-
tion in hMDMs from patients in all the TB-associated groups,
and when the cytokine data from all study groups were com-
bined, there was a significant increase of the 1,25D3-stimu-
lated levels of IL-1b and IL-10 (p = 0.0017 and p = 0.0008,
respectively, Fig. 3E). The combined analysis further revealed
that the concentration of IL-12p40 (p = 0.046) and TNF-a
(p = 0.082) in the supernatant slightly increased upon 1,25D3
stimulation (Fig. 3E).Discussion
In the present study, the capacity of hMDMs from patients
with or without TB to control the growth of MTB and whether
or not such growth inhibition could be enhanced in the
presence of 1,25D3 was investigated. Although the first obser-
vations of vitamin D stimulation of monocyte and macro-
phage anti-mycobacterial activity is more than 25 years old
[14,15], this is the first study where this activity of hMDMs
from patients with current TB was investigated.
Due to its relatively short half-life, one dose of 100 nM
1,25D3 was used throughout the study; 1,25D3 in this range
has previously been shown to be required for effective stimu-
lation of primarymonocytes [16]. It was observed that hMDMs
from patients with active TB, when stimulated with 1,25D3,
were more effective in controlling MTB infection. This effect
was not seen in hMDMs from the other groups, despite the
fact that all groups showed a tendency to respond to 1,25D3
by enhancing IL-1b production, with a significant increase in
the non-TB group. Enhanced production of IL-1b by 1,25D3
has been demonstrated before, with a necessary lipopolysac-
charide priming step [17]. The pro-inflammatory properties of
IL-1b are mediated through the IL-1 receptor 1 (IL1R1) and is
important in the protection against MTB [18,19]. IL1R1 shares
signaling partners, including Myd88, with TLRs, and in vivo
studies have suggested that mice lacking Myd88 are highly
susceptible to MTB not because of the inability to signal
through TLRs, as earlier thought, but rather because of the
inability to signal through IL-1R1 [20]. It is possible that the
in vivo preconditioning of monocytes in hosts with replicating
MTB, as is the case in the patients with active TB, primes the
monocytes for a more efficient antimicrobial response. In
fact, studies have shown that TLR1/2 engagement, in addition
to the role of up-regulation of VDR expression, is also able to
sensitize cells to IL-1b stimulation. This sensitization together
with 1,25D3 stimulation leads to the expression of the antimi-
crobial peptide, beta-Defensin 4 [16]. It is tempting to
Fig. 3 – Cytokine release upon infection by H37Rv with and without stimulation by 1,25 D3. hMDMs were infected with H37Rv
at MOI 10, before supernatants were harvested 24 h post-infection and concentrations of TNF-a, IL-b, IL-10 and IL-12p40 were
determined by BD CBA Flex Set. The figure shows the mean concentrations of (A) IL-b, (B) TNF-a, (C) IL-10 and (D) IL-12p40
from each group, with and without 1,25D3. (E) The panel shows the total mean concentration of the respective cytokine
between all non-stimulated and stimulated samples. Non-TB (n = 5), previous TB (n = 3), current TB (n = 6) and latent TB (n = 3).
Bar graphs show the mean and SEM. The means between different groups were compared using ANOVA with Bonferroni’s
post hoc test. To evaluate the effects of 1,25D3 stimulation within each group and comparison of the total non-stimulated
with stimulated samples, a paired Student’s t-test was used.
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could render the macrophages more sensitive to inflamma-
tory signals, such as 1,25D3-induced IL-1b, leading to
increased expression of anti-microbial peptides and the
decreased bacterial growth in the active TB group. It would
be of interest to measure the expression of anti-microbial
peptides in response to 1,25D3 stimulation in future studies
and to investigate if this is truly mediated through IL-1b.
Furthermore, there was a clear induction of IL-10 in
hMDMs from the non-TB and current TB group. IL-10, to-
gether with the IL-10 receptor, has been shown to be inducedby 1,25D3 [21,22]. This 1,25D3-induced up-regulation of IL-10
has been proposed to represent a protective mechanism in
TB, where IL-10 inhibits the increased expression of matrix
metalloproteinases by MTB, thereby limiting the tissue dam-
age and subsequent pulmonary cavitation [23]. However, the
effects of IL-10 in vitro might be more detrimental to the cells
since it can inhibit the phagosomal maturation process of
macrophages infected with MTB [24], a process counteracted
by pro-inflammatory signals or effector molecules. Blocking
IL-10 signaling in the in vitro system would help to clarify
whether or not IL-10 is indeed counteracting the effects of
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bial peptides in hMDMs.
Although this study displays a small sample size and the
number of cells obtained from the patients is limited, the in-
cluded study subjects are well characterized clinically, and
these study groups were categorized in a blinded fashion,
with no knowledge of experimental data. No differences be-
tween the different study groups were seen in regard to sex,
ethnicity, age, BMI, or other general confounder. Of interest,
no significant differences were seen in the serum levels of
25-hydroxyvitamin D in the limited study population and as
reported elsewhere [25]: levels varied considerably between
subjects with no obvious pattern between study groups. So
far, there is no proven causality between low serum vitamin
D levels and susceptibility to TB, as both healthy individuals
and TB patients may have low serum levels of vitamin D.
However, this data suggests that unrelated to the levels of
vitamin D in serum, there might be clear differences in how
cells from both individual patients and different patient
groups respond to the supplementation of vitamin D. It would
be of interest to study if hMDMs would become less respon-
sive to 1,25D3 stimulation after patients have undergone
treatment, thereby lowering the inflammatory state of the
host.
Today, there is no ‘‘gold standard’’ for diagnosis of latent
TB; TST and chest X-ray remain the primary screening tools
[7]. In the present study, all latent TB subjects had a history
of a previous TB contact and a normal chest X-ray; 5 of 6 dis-
played a TSTP 10 mm, and the remaining case had a positive
IGRA. One subject in the non-TB group was IGRA-positive.
However, lacking all other indications of TB, it was decided
to define this subject as a non-TB subject.
This study has several limitations, including the small
study sample, and the impact of 1,25D3 stimulation on bacte-
rial growth is, although clear, relatively small. Considering the
slow growth of MTB, this relatively small effect might be
influenced by the early time point at which bacterial growth
was measured. It was chosen to measure bacterial growth
at day 2 post-infection, since it was previously shown that be-
yond this time point, less than 10% of hMDMs are viable when
infected at an MOI of 10 [13]. However, if possible, it would be
of interest to extend the incubation time to evaluate if differ-
ences between 1,25D3 stimulated and non-stimulated cells
become more pronounced with respect to both bacterial
growth and cytokine responses. Another factor that might
hide possible differences in the ability to control growth is
the MOI. It was previously shown that the MOI greatly influ-
ences the outcome of MTB infection in hMDMs [12], and it
would be of interest to lower the bacteria-to-cell ratio in order
to investigate the effect of 1,25D3 stimulation under such
conditions. For future studies, it would also be interesting to
investigate whether or not 1,25D3 stimulation affects cell
death of hMDMs and how this might potentially relate to bac-
terial growth.
In a parallel study, the anti-mycobacterial activity of alve-
olar macrophages obtained from broncho lavage fluid from
some of the patients in the present study was investigated.
As opposed to the finding that hMDMs from patients with cur-
rent TB were better suited to controlling MTB infection in this
study, alveolar macrophages from patients with a history ofTB were in fact less capable of limiting bacterial growth at
MOI 10 two days post-infection compared with the control
group (unpublished observation). An important difference be-
tween hMDMs (as in the present study) and isolated alveolar
macrophages is that the latter are differentiated in vivo,
whereas hMDMs are differentiated in vitro with serum pooled
from five healthy donors. The fact that the same serum was
used for differentiation of cells from all study groups may
contribute to masking possible differences.
Taken together, the current study suggests that circulating
monocytes from TB patients might be primed and sensitized
to the effects of 1,25D3 stimulation, such as increased IL-1b
secretion, while the parallel study suggests that when these
monocytes leave circulation and migrate into the lungs of
(current or previous) TB patients, the microenvironment in
the lungs of these particular patients renders macrophages
less able to control growth of MTB, overriding the beneficial
effects of the possible priming event.
Conclusion
It was concluded that vitamin D triggers an inflammatory re-
sponse in human macrophages with enhanced secretion of
IL-1b, and that in patients with ongoing TB, hMDMs can re-
strict MTB growth more effectively upon vitamin D stimula-
tion. Further studies are needed to clarify the importance of
the presence of infection in the host and its immune status
for later antimicrobial response of in vitro-differentiated
macrophages.
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